Case report

Should MS be Treated by Escalation or Induction Therapy?

Ines Lazibat ; University of Zagreb, University Hospital Dubrava, Department of Neurology, Zagreb, Croatia
Branimir Nevajda ; University of Zagreb, University Hospital Dubrava, Department of Neurology, Zagreb, Croatia
Gordan Grahovac ; University of Zagreb, University Hospital Dubrava, Department of Neurology, Zagreb, Croatia
Vesna V. Brinar ; University of Zagreb, School of Medicine, Zagreb, Croatia

Abstract

MS is a chronic, increasingly disabling disease whose long-term outcomes determine the key social, medical and economic impact of this disease. Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are prescribed to delay disease progression and to protect a patient’s functional capability. The concepts of escalation and induction immunotherapy in MS represent different therapeutic strategies for the treatment of MS. Both strategies may be valuable options for patients starting on DMT, however, induction therapy mainly focuses on patients with very aggressive course of MS from the onset. Using a patient unique approach to selection of treatment, MS can be effectively control disease and may delay or even prevent the development of secondary progressive MS.

Keywords

Disease-modifying therapy; multiple sclerosis; escalation therapy; induction therapy

Hrčak ID:

120930

URI

https://hrcak.srce.hr/120930

Publication date:

31.3.2014.

Visits: 1.820 *